The increased use of anti-HIV-1 treatments in developing countries primarily infected by non-B subtypes necessitates development of novel tools to assess susceptibility and resistance. HIV-1 genomes are highly polymorphic and present challenges for the development of universal protocols capable of screening across subtypes. Currently available viral genotyping methods are useful for viral quantification, but are inadequate for sequence profiling or comprehensive mutation detection in the variable regions of HIV polymerase (pol).
Methods
A novel set of universal primers within pol, with consensus among a variety of HIV-1 subtypes, was developed. One-round amplification was performed by one-step reverse transcription PCR on 79 samples from HIV-1 subtypes. Using a second set of primers, the amplified fragment was sequenced and assembled to produce a profile database per sample.
Results
First-round amplification using universal primers generated a unique amplicon encompassing the major pol regions in all tested HIV-1 subtype samples. Sequence analysis of the amplified fragment not only confirmed the subtype of each HIV-1 isolate but also identified resistance mutations in the pol genes of HIV-1, including protease, reverse transcriptase, connection, RNase H, and integrase. Last, some of these primers were used to develop a viral load test using quantitative real time-PCR.
Conclusions
A novel protocol was produced to effectively identify and simultaneously generate extensive sequence profiles of pol genes across HIV-1 subtypes. This protocol allows for expeditious and cost-effective mutation detection, genotypic evaluation and viral load determination in multiple HIV-1 subtypes.
References
1.
Martínez-CajasJ.L., Pant-PaiN., KleinM.B., WainbergM.A.Role of genetic diversity amongst HIV-1 non-B subtypes in drug resistance: a systematic review of virologic and biochemical evidence. AIDS Rev2008; 10: 212–223.
2.
KantorR., KatzensteinD.Drug resistance in non-subtype B HIV-1. J Clin Virol2004; 29: 152–159.
3.
KatzensteinD.Diversity, drug resistance, and the epidemic of subtype C HIV-1 in Africa. J Infect Dis2006; 194Suppl 1: S45–S50.
4.
SpiraS., WainbergM.A., LoembaH., TurnerD., BrennerB.G.Impact of clade diversity on HIV-1 virulence, antiretroviral drug sensitivity and drug resistance. J Antimicrob Chemother2003; 51: 229–240.
5.
BrennanC.A., StramerS.L., HolzmayerV.Identification of human immunodeficiency virus type 1 non-B subtypes and antiretroviral drug-resistant strains in United States blood donors. Transfusion2009; 49: 125–133.
6.
OsmanovS., PattouC., WalkerN., SchwardländerB., EsparzaJ.Estimated global distribution and regional spread of HIV-1 genetic subtypes in the year 2000. J Acquir Immune Defic Syndr2002; 29: 184–190.
7.
LuW., CaoL., TyL., ArlieM., AndrieuJ.M.Equivalent amplification of intrinsically variable nucleic acid sequences by multiple-primer-induced overlapping amplification assay: applications for universal detection and quantitation. Nat Med1999; 5: 1081–1085.
8.
TangN., HuangS., SalituroJ.A RealTime HIV-1 viral load assay for automated quantitation of HIV-1 RNA in genetically diverse group M subtypes A-H, group O and group N samples. J Virol Methods2007; 146: 236–245.
9.
Van LaethemK., SchrootenY., CovensK.A genotypic assay for the amplification and sequencing of integrase from diverse HIV-1 group M subtypes. J Virol Methods2008; 153: 176–181.
10.
KantorR., KatzensteinD.Polymorphism in HIV-1 non-subtype B protease and reverse transcriptase and its potential impact on drug susceptibility and drug resistance evolution. AIDS Rev2003; 5: 25–35.
11.
FishM.Q., HewerR., WallisC.L., VenterW.D., StevensW.S., PapathanasopoulosM.A.Natural polymorphisms of integrase among HIV type 1-infected South African patients. AIDS Res Hum Retroviruses2010; 26: 489–493.
12.
NkololaJ.P., EssexM.Progress towards an HIV-1 subtype C vaccine. Vaccine2006; 24: 391–401.
13.
WainbergM.A.HIV-1 subtype distribution and the problem of drug resistance. AIDS2004; 18Suppl 3: S63–S68.
14.
KantorR., MachekanoR., GonzalesM.J., DupnikK., SchapiroJ.M., ShaferR.W.Human immunodeficiency virus reverse transcriptase and protease sequence database: an expanded data model integrating natural language text and sequence analysis programs. Nucleic Acids Res2001; 29: 296–299.
15.
WittekM., StürmerM., DoerrH.W., BergerA.Molecular assays for monitoring HIV infection and antiretroviral therapy. Expert Rev Mol Diagn2007; 7: 237–246.
16.
RheeS.Y., LiuT.F., KiuchiM.Natural variation of HIV-1 group M integrase: implications for a new class of antiretroviral inhibitors. Retrovirology2008; 5: 74.
17.
RoquebertB., MarcelinA.G.The involvement of HIV-1 RNAse H in resistance to nucleoside analogues. J Antimicrob Chemother2008; 61: 973–975.
18.
SantosA.F., LengruberR.B., SoaresE.A.Conservation patterns of HIV-1 RT connection and RNase H domains: identification of new mutations in NRTI-treated patients. PLoS One2008; 3: e1781.
19.
YapS.H., SheenC.W., FaheyJ.N348I in the connection domain of HIV-1 reverse transcriptase confers zidovudine and nevirapine resistance. PLoS Med2007; 4: e335.
20.
TebitD.M., NankyaI., ArtsE.J., GaoY.HIV diversity, recombination and disease progression: how does fitness ‘fit’ into the puzzle?AIDS Rev2007; 9: 75–87.
21.
ZhangH.W., CoatsS.J., BondadaL.Synthesis and evaluation of 3′-azido-2′,3′-dideoxypurine nucleosides as inhibitors of human immunodeficiency virus. Bioorg Med Chem Lett2010; 20: 60–64.
22.
LeozM., DepatureauxA., VessièreA.Integrase polymorphism and HIV-1 group O diversity. AIDS2008; 22: 1239–1243.
23.
Bar-MagenT., SloanR.D., DonahueD.A.Identification of novel mutations responsible for resistance to MK-2048, a second-generation HIV-1 integrase inhibitor. J Virol2010; 84: 9210–9216.
24.
YusaK., HaradaS.Acquisition of multi-PI (protease inhibitor) resistance in HIV-1 in vivo and in vitro. Curr Pharm Des2004; 10: 4055–4064.
25.
Lambert-NiclotS., FlandreP., MaletI.Impact of gag mutations on selection of darunavir resistance mutations in HIV-1 protease. J Antimicrob Chemother2008; 62: 905–908.
